ARV-471
Arvinas · HR+ breast cancer
AI approach: AI-prioritised E3 ligase recruiter
Topline readout · Apr 2026
Pipeline Dashboard
AI drug discovery pipeline
Every AI-discovered or AI-optimised program we can identify, grouped by modality and clinical phase. Updated daily from ClinicalTrials.gov + company disclosures.
847 programs tracked
Modality
Preclinical
426 total
Phase 1
229 total
Phase 2
120 total
Phase 3
48 total
Approved
24 total
Total
PROTAC
48
22
7
2
—
79
ADC
62
41
24
9
3
139
mRNA
38
18
8
3
2
69
Gene therapy
44
19
9
3
2
77
Cell therapy
52
28
16
5
1
102
Molecular glue
19
6
1
—
—
26
Radiopharma
17
9
4
2
1
33
Small molecule
78
44
26
11
6
165
Antibody
54
36
22
12
8
132
Peptide
14
6
3
1
1
25
Recently advanced
REC-2282
Recursion · NF2-mutated meningioma
AI approach: Phenomics-driven target + active learning
Advanced to Phase 2 · Mar 2026
RLY-2608
Relay Therapeutics · PI3Kα-mutated solid tumours
AI approach: Dynamics-informed allosteric design
Interim analysis · Apr 2026
XAI-001
Xaira Therapeutics · Undisclosed autoimmune
AI approach: AF3 + generative antibody design
IND-enabling · Apr 2026
REC-994
Recursion · Cerebral cavernous malformation
AI approach: Phenomics hit → AF3-guided SAR
Phase 2 interim · Mar 2026
INS018_055
Insilico Medicine · Idiopathic pulmonary fibrosis
AI approach: Generative chemistry + TDT-prioritised
Phase 2a complete · Apr 2026